Effects of resuvastatin and tigrelol on the cardiac function and blood lipid of coronary heart disease patients treated by percutaneous coronary intervention

Objective To analyze the effects of resuvastatin and tigrelol on the cardiac function and blood lipid of coronary heart disease patients treated by percutaneous coronary intervention (PCI). Methods A total of 128 coronary heart disease patients were selected, who were admitted into Zhongda Hospital Affiliated to Southeast University from January 2016 to March 2018 and underwent coronary stent implantation. According to the random number table method, they were randomly divided into two groups(n=64): an observation group and a control group. After admission, all patients received basic treatment. Furthermore, the control group was orally taken resuvastatin+biaspirin+clopidogrel before surgery, while the observation group was orally taken resuvastatin+biaspirin+tigrelol before surgery. Both groups were continuously treated with resuvastatin for 6 months. Then, the two groups were compared for blood lipid level, restenosis rate, cardiac function index and platelet aggregation function, and cardiovascular adverse events were recorded. Results Six months after PCI treatment, remarkably decreased laveles of TC, TG and LDL-C and marked increased laveles of HDL-C were found in the two groups compared with pre-treatment levels (P<0.05). There were two cases of restenosis in the control group and one case of restenosis in the observation group, without statistical difference (P>0.05). Six months after PCI treatment, both groups presented significantly higher levels of left ventricular ejection fraction (LVEF) and markedly lower levels of N-terminal pro-BNP (NT-BNP) compared with pre-treatment levels (P<0.05). Compared with the control group, the observation group produced significantly increased LEVF and decreased NT-BNP, with statistical difference (P<0.05). Six months after PCI treatment, both groups presented remarkable decreases in the maximum platelet aggregation rate compared with pre-treatment levels (P<0.05)。Compared with the control group in the same period, the maximum platelet aggregation rate in the observation group was significantly lower (P<0.05); and the total incidence of adverse cardiovascular events in the observation group was significantly lower than that in the control group (P <0.05). Conclusions The combined treatment of coronary heart disease patients by PCI with resuvastatin and tigrelol can effectively reduce the incidence of stenosis, improve blood lipid and heart function, improve the anti-platelet aggregation, and have high safety.